Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients Begins with Promising Initial Data
Following to the previous information on September 10th. 2024, we are excited to share our latest development status.
Enrollment of patients is progressing smoothly into the Phase I portion of the Phase I/II study of DFP-10917 combined with Venetoclax in AML patients previously treated with Venetoclax, one regimen. The first three patients are showing encouraging safety and efficacy results suggested further promising development.
The existing standard combination chemotherapy for AML patients is Azacitidine and Venetoclax, but it is not comfortable for AML patients. We’re trying to do a combination of DFP-10917 with Venetoclax, as an alternative safer AML therapy, objective NDA approval from the FDA in the US under possible collaboration with a global mega-pharma.
The Phase III study of DFP-10917 in relapsed/refractory AML patients is planned data cut-off as decreasing in the number of long-term survivors since then.
Please take notice of our own innovative approach for miserable cancer patients and contact us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028538375/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TRU Simulation delivers Full-Flight Simulator to Royal Flying Doctor Service (RFDS) (Queensland Section)28.10.2024 15:50:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE: TXT) company, announced today Australia’s Civil Aviation Safety Authority (CASA) has awarded Level D certification of a Full-Flight Simulator (FFS) to the Royal Flying Doctor Service (RFDS Queensland Section). The FFS is reconfigurable to support training for the entire fleet of RFDS Queensland Section Beechcraft King Air model B200 and B300 aircraft. The simulator is the first of its kind in Australia and is housed in a new, purpose-built training facility next to the RFDS base in Bundaberg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241028764231/en/ TRU Simulation delivers Full-Flight Simulator to Royal Flying Doctor Service (RFDS) (Queensland Section) (Photo: Business Wire) TRU Simulation, an affiliate of Textron Aviation Inc., the manufacturer of Beechcraft King Air aircraft, designs, manufactures and delivers high-fidelity training devices and full-motion simulat
Armis Raises $200M at $4.2B Valuation as Growth Soars, Eyes IPO28.10.2024 15:32:00 CET | Press release
Company continues to grow rapidly, closes a new funding round Armis, the cyber exposure management & security company, announced today the close of a $200 million Series D round of investment, increasing its total company valuation to a new high of $4.2 billion. Armis' latest funding round was led by both top-tier investors General Catalyst and Alkeon Capital, along with existing investors Brookfield Technology Partners and Georgian. The additional capital will enable Armis to continue with its 5 year strategy to build a multi-generational cybersecurity company, fuel strong organic product innovation and global go-to-market programs, while simultaneously taking advantage of game changing inorganic growth opportunities that may arise. Armis’ ability to offer unmatched visibility, security, and risk management to enterprises across all industries has made it a standout leader in the fast-evolving cybersecurity landscape. As the trusted cybersecurity partner of the world’s largest organiz
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%28.10.2024 14:25:00 CET | Press release
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S. Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. Please see our prior announcement for a summary of the transaction terms. VTAMA® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaque psoriasis in adults with no safety label warnings or precautions and without restrictions on location and duration of use or body surface area. The FDA is reviewing a supplemental New Drug Application (sNDA) for VTAMA cream as a potential treatment for
Hyatt and Grupo Piñero Announce Plans to Form Strategic Venture for Growth of Bahia Principe Hotels & Resorts Brand28.10.2024 14:00:00 CET | Press release
Strategic joint venture will strengthen Hyatt’s position as a global leader in the all-inclusive space and boost the growth of Grupo Piñero's hotel division and its ability to reach new clients in key markets Hyatt Hotels Corporation (NYSE: H) today announced plans for affiliates of Hyatt and Grupo Piñeroto enter into a long-term asset-light strategic joint venture, headquartered in Palma de Mallorca, Spain, which will manage Bahia Principe-branded hotels and resorts and own the Bahia Principe brand. The 50/50 joint venture is expected to expand Hyatt’s all-inclusive room portfolio by approximately 30% and enhance Hyatt’s position as one of the leading providers of all-inclusive offerings across the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241028228577/en/ Bahia Principe Grand El Portillo, Dominican Republic. (Credit: Grupo Piñero) For Grupo Piñero, this strategic venture will build on the company’s longstanding
Experian Launches New GenAI Solution to Greatly Accelerate the Modeling Lifecycle28.10.2024 14:00:00 CET | Press release
Improves data scientist productivity and model monitoring, empowers data analysts to easily query data and write code At this week’s Money 20/20 show in Las Vegas, Experian® today announced the launch of Experian Assistant, a new generative AI-enabled solution that greatly accelerates the modeling lifecycle, slashing model-development timelines from months to days and — in some cases — hours. Integrated with Experian Ascend Technology Platform™, this transformative solution empowers users to further leverage their data for analytics faster and with less effort than ever before. The world’s largest financial institutions use Experian Ascend™. In close collaboration with several customers, Experian Assistant was developed to offer a deeper understanding of credit and fraud data and provide criteria and proposals for adding; changing the weight of; or deleting specific attributes, data, or features to optimize analytical models. In addition, this innovative solution helped increase intern
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom